)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Xintela
Xintela (XINT) investor relations material
Xintela Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Net sales increased to SEK 1,317 thousand in Q2 2026, up from SEK 872 thousand year-over-year, driven by the EQGen project.
Loss before tax improved to SEK -9,762 thousand from SEK -12,119 thousand year-over-year due to higher sales and lower costs.
XSTEM achieved its primary safety objective in a clinical study for difficult-to-heal venous leg ulcers.
Positive results from the knee osteoarthritis study with XSTEM were published, supporting disease-modifying effects.
SEK 30 million convertible loan secured from principal shareholder to accelerate XSTEM development and repay previous debt.
Financial highlights
Net sales for Q2 2026: SEK 1,317 thousand (Q2 2025: SEK 872 thousand).
Loss before tax for Q2 2026: SEK -9,762 thousand (Q2 2025: SEK -12,119 thousand).
Loss per share for Q2 2026: SEK -0.01 (Q2 2025: SEK -0.02).
Cash and cash equivalents at June 30, 2026: SEK 30,724 thousand (June 30, 2025: SEK 10,532 thousand).
Operating loss for Q2 2026: SEK -9,683 thousand (Q2 2025: SEK -11,526 thousand).
Outlook and guidance
Focus on accelerating XSTEM's path to market through business development and partnerships.
Strategy includes early commercialization in select markets and ongoing efforts to secure further funding.
Continued development of XSTEM for wound indications is planned primarily through strategic partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Xintela
- XSTEM met key clinical milestones and secured new patents, supporting future commercialization.XINT
Q1 2026 - XSTEM clinical results drive partnership interest as financial losses widen but funding is secured.XINTQ4 2025
- XSTEM delivered long-term efficacy in osteoarthritis, with ongoing clinical and partnership progress.XINTQ3 2025
- XSTEM's highest dose halted cartilage loss and improved bone structure in OA patients for two years.XINTInvesting in Life Science 2025
- XSTEM osteoarthritis study completed; strong warrant uptake boosts cash amid ongoing losses.XINTQ2 2025
- Improved results, clinical progress, and new financing position Xintela for next-stage growth.XINTQ3 2024
- Losses narrowed as Xintela advanced clinical programs and secured new development agreements.XINTQ2 2024
- XSTEM's 18-month osteoarthritis results and EQSTEM's global licensing drive Xintela's Q1 progress.XINTQ1 2025
- Xintela reached key clinical milestones and strengthened its finances while pursuing new partnerships.XINTQ4 2024
Next Xintela earnings date
Q3 202627 Nov, 2026
Xintela
Next Xintela earnings date
Q3 202627 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage